Eli Lilly agreed to acquire Ajax Therapeutics for up to $2.3 billion, adding a next-generation JAK2 inhibitor program for myeloproliferative neoplasms to its hematology pipeline. The deal brings Lilly exposure to AJ1-11095, a Type II JAK2 inhibitor that is in Phase 1 testing for myelofibrosis. The transaction extends Lilly’s recent acquisition pace in areas where differentiation may be limited in existing classes. For Ajax, the sale provides scale and development resources as AJ1-11095 advances, with investors focused on whether deeper and more durable disease control translates into later registrational success. From a sector standpoint, the Ajax buy reinforces a continued strategy by large pharma to strengthen late-stage hematology and reduce dependence on existing standards of care that have faced incremental competitive pressure.